Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EBT (2017 - 2025)

Arcus Biosciences has reported EBT over the past 9 years, most recently at -$106.0 million for Q4 2025.

  • Quarterly results put EBT at -$106.0 million for Q4 2025, down 13.98% from a year ago — trailing twelve months through Dec 2025 was -$353.0 million (down 25.18% YoY), and the annual figure for FY2025 was -$353.0 million, down 25.18%.
  • EBT for Q4 2025 was -$106.0 million at Arcus Biosciences, up from -$135.0 million in the prior quarter.
  • Over the last five years, EBT for RCUS hit a ceiling of $281.5 million in Q4 2021 and a floor of -$135.0 million in Q3 2025.
  • Median EBT over the past 5 years was -$76.0 million (2021), compared with a mean of -$60.4 million.
  • Peak annual rise in EBT hit 641.47% in 2021, while the deepest fall reached 4379.64% in 2021.
  • Arcus Biosciences' EBT stood at $281.5 million in 2021, then crashed by 123.8% to -$67.0 million in 2022, then dropped by 19.4% to -$80.0 million in 2023, then dropped by 16.25% to -$93.0 million in 2024, then dropped by 13.98% to -$106.0 million in 2025.
  • The last three reported values for EBT were -$106.0 million (Q4 2025), -$135.0 million (Q3 2025), and -$112.0 million (Q1 2025) per Business Quant data.